{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:18:38Z","timestamp":1764645518827},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00393-020-00837-9","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T12:05:05Z","timestamp":1594296305000},"page":"776-784","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis"],"prefix":"10.1007","volume":"80","author":[{"given":"Y. H.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. G.","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"issue":"8","key":"837_CR1","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson\u00a0JJ, Baron\u00a0G, van der Heijde\u00a0D et al (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44(8):1876\u20131886","journal-title":"Arthritis Rheum"},{"issue":"9906","key":"837_CR2","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten\u00a0D, Baraliakos\u00a0X, Braun\u00a0J et al (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a\u00a0randomised, double-blind, placebo-controlled trial. Lancet 382(9906):1705\u20131713","journal-title":"Lancet"},{"issue":"26","key":"837_CR3","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten\u00a0D, Sieper\u00a0J, Braun\u00a0J et al (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N\u00a0Engl J Med 373(26):2534\u20132548","journal-title":"N Engl J Med"},{"issue":"6","key":"837_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun\u00a0J, van den Berg\u00a0R, Baraliakos\u00a0X et\u00a0al (2011) 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6):896\u2013904","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"837_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/2046-4053-3-110","volume":"3","author":"S Brown","year":"2014","unstructured":"Brown\u00a0S, Hutton\u00a0B, Clifford\u00a0T et al (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses\u2014an overview and application of NetMetaXL. Syst Rev 3(1):110","journal-title":"Syst Rev"},{"issue":"2","key":"837_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4078\/jrd.2018.25.2.131","volume":"25","author":"S Byun","year":"2018","unstructured":"Byun\u00a0S, Jung\u00a0SM, Song\u00a0JJ et\u00a0al (2018) Hemoglobin A1c, not Glycated albumin, Can independently reflect the Ankylosing Spondylitis disease activity score. J\u00a0Rheum Dis 25(2):131\u2013139","journal-title":"J Rheum Dis"},{"issue":"7521","key":"837_CR7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell\u00a0DM, Ades\u00a0AE, Higgins\u00a0JP (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331(7521):897\u2013900","journal-title":"BMJ"},{"issue":"4","key":"837_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar\u00a0A, Poddubnyy\u00a0D, Pacheco-Tena\u00a0C et al (2019) Efficacy and safety of Ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a\u00a0phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol 71(4):599\u2013611","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"837_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias\u00a0S, Welton\u00a0NJ, Sutton\u00a0AJ et\u00a0al (2013) Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33(5):641\u2013656","journal-title":"Med Decis Making"},{"issue":"2","key":"837_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/1744666X.2019.1561281","volume":"15","author":"S Dubash","year":"2019","unstructured":"Dubash\u00a0S, Bridgewood\u00a0C, McGonagle\u00a0D et al (2019) The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. Expert Rev Clin Immunol 15(2):123\u2013134","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"837_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4078\/jrd.2018.25.4.221","volume":"25","author":"Y-S Hahn","year":"2018","unstructured":"Hahn\u00a0Y\u2011S (2018) Enthesitis-related Arthritis. J\u00a0Rheum Dis 25(4):221\u2013230","journal-title":"J Rheum Dis"},{"issue":"10163","key":"837_CR12","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"Heijde\u00a0D van der, Wei\u00a0JC\u2011C, Dougados\u00a0M et al (2018) Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a\u00a0phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 392(10163):2441\u20132451","journal-title":"Lancet"},{"issue":"2","key":"837_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JP Higgins","year":"2012","unstructured":"Higgins\u00a0JP, Jackson\u00a0D, Barrett\u00a0JK et al (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3(2):98\u2013110","journal-title":"Res Synth Methods"},{"issue":"3","key":"837_CR14","first-page":"142","volume":"22","author":"A Kivitz","year":"2016","unstructured":"Kivitz\u00a0A, Blanco\u00a0R, Maradiaga\u00a0M et al (2016) Secukinumab provides sustained improvement in physical, function, health-related quality of life, fatigue, and work productivity in patients with active psoriatic arthritis: 52-week results from an international phase 3 trial. J\u00a0Clin Rheumatol 22(3):142\u2013143","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"837_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","volume":"5","author":"AJ Kivitz","year":"2018","unstructured":"Kivitz\u00a0AJ, Wagner\u00a0U, Dokoupilova\u00a0E et al (2018) Efficacy and safety of secukinumab 150\u202fmg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther 5(2):447\u2013462","journal-title":"Rheumatol Ther"},{"issue":"1","key":"837_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4078\/jrd.2018.25.1.28","volume":"25","author":"BS Koo","year":"2018","unstructured":"Koo\u00a0BS, Lim\u00a0JW, Shin\u00a0JH et al (2018) Characteristics of uveitis in patients with ankylosing spondylitis in Korea: a\u00a0single-center survey. J\u00a0Rheum Dis 25(1):28\u201333","journal-title":"J Rheum Dis"},{"issue":"4","key":"837_CR17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley\u00a0RG, Elewski\u00a0BE, Lebwohl\u00a0M et\u00a0al (2014) Secukinumab in plaque psoriasis\u2014results of two phase 3 trials. N\u00a0Engl J Med 371(4):326\u2013338","journal-title":"N Engl J Med"},{"issue":"3","key":"837_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4078\/jrd.2018.25.3.169","volume":"25","author":"YH Lee","year":"2018","unstructured":"Lee\u00a0YH (2018) Association between the neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio and rheumatoid arthritis and their correlations with the disease activity: a meta-analysis. J\u00a0Rheum Dis 25(3):169\u2013178","journal-title":"J Rheum Dis"},{"issue":"1","key":"837_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4078\/jrd.2020.27.1.37","volume":"27","author":"YH Lee","year":"2020","unstructured":"Lee\u00a0YH, Song\u00a0GG (2020) Associations Between Circulating Interleukin-17 Levels and Systemic Lupus Erythematosus and Between Interleukin-17 Gene Polymorphisms and Disease Susceptibility: A Meta-analysis. J\u00a0Rheum Dis 27(1):37\u201344","journal-title":"J Rheum Dis"},{"issue":"4","key":"837_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4078\/jrd.2017.24.4.211","volume":"24","author":"YH Lee","year":"2017","unstructured":"Lee\u00a0YH, Song\u00a0GG (2017) Comparative efficacy and safety of secukinumab and adalimumab in patients with active ankylosing spondylitis: a\u00a0Bayesian network meta-analysis of randomized controlled trials. J\u00a0Rheum Dis 24(4):211\u2013219","journal-title":"J Rheum Dis"},{"issue":"3","key":"837_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4078\/jrd.2018.25.3.197","volume":"25","author":"YH Lee","year":"2018","unstructured":"Lee\u00a0YH, Song\u00a0GG (2018) Overall and sex-specific mortality in psoriatic arthritis and ankylosing spondylitis: A meta-analysis. J\u00a0Rheum Dis 25(3):197\u2013202","journal-title":"J Rheum Dis"},{"issue":"4","key":"837_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4078\/jrd.2019.26.4.257","volume":"26","author":"YH Lee","year":"2019","unstructured":"Lee\u00a0YH, Song\u00a0GG (2019) YKL-40 Levels in Rheumatoid Arthritis and Their Correlation with Disease Activity: A Meta-analysis. J\u00a0Rheum Dis 26(4):257\u2013263","journal-title":"J Rheum Dis"},{"key":"837_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","volume":"9","author":"L Liu","year":"2016","unstructured":"Liu\u00a0L, Lu\u00a0J, Allan\u00a0BW et al (2016) Generation and characterization of ixekizumab, a\u00a0humanized monoclonal antibody that neutralizes interleukin-17A. J\u00a0Inflamm Res 9:39","journal-title":"J Inflamm Res"},{"issue":"4","key":"837_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher\u00a0D, Liberati\u00a0A, Tetzlaff\u00a0J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264\u2013269","journal-title":"Ann Intern Med"},{"issue":"5","key":"837_CR25","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/bjd.16497","volume":"178","author":"C Paul","year":"2018","unstructured":"Paul\u00a0C (2018) Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatology 178(5):1003\u20131005","journal-title":"Br J Dermatology"},{"issue":"1","key":"837_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","volume":"19","author":"K Pavelka","year":"2017","unstructured":"Pavelka\u00a0K, Kivitz\u00a0A, Dokoupilova\u00a0E et al (2017) Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a\u00a0randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther 19(1):285","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"837_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti\u00a0G, Ades\u00a0AE, Ioannidis\u00a0JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J\u00a0Clin Epidemiol 64(2):163\u2013171","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"837_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2011-200228","volume":"71","author":"S Schmitz","year":"2012","unstructured":"Schmitz\u00a0S, Adams\u00a0R, Walsh\u00a0CD et al (2012) A\u00a0mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a\u00a0Bayesian approach. Ann Rheum Dis 71(2):225\u2013230","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"837_CR29","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/art.24568","volume":"60","author":"H Shen","year":"2009","unstructured":"Shen\u00a0H, Goodall\u00a0JC, Hill\u00a0GJS (2009) Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 60(6):1647\u20131656","journal-title":"Arthritis Rheum"},{"issue":"3","key":"837_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.berh.2006.02.001","volume":"20","author":"J Sieper","year":"2006","unstructured":"Sieper\u00a0J, Rudwaleit\u00a0M, Khan\u00a0MA et\u00a0al (2006) Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol 20(3):401\u2013417","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"12","key":"837_CR31","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s10067-012-2080-7","volume":"31","author":"GG Song","year":"2012","unstructured":"Song\u00a0GG, Bae\u00a0S\u2011C, Lee\u00a0YH (2012) Association between vitamin D intake and the risk of rheumatoid arthritis: a\u00a0meta-analysis. Baillieres Clin Rheumatol 31(12):1733\u20131739","journal-title":"Baillieres Clin Rheumatol"},{"issue":"4","key":"837_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G van Valkenhoef","year":"2012","unstructured":"Valkenhoef\u00a0G van, Lu\u00a0G, de Brock\u00a0B et al (2012) Automating network meta-analysis. Res Synth Methods 3(4):285\u2013299","journal-title":"Res Synth Methods"},{"key":"837_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2014.08.003","author":"D Wendling","year":"2015","unstructured":"Wendling\u00a0D, Guillot\u00a0X, Prati\u00a0C (2015) The IL-23\/Th 17 pathway in spondyloarthritis: the royal road? Joint Bone Spine. https:\/\/doi.org\/10.1016\/j.jbspin.2014.08.003","journal-title":"Joint Bone Spine"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00837-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-020-00837-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00837-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T16:48:29Z","timestamp":1633711709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-020-00837-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["837"],"URL":"https:\/\/doi.org\/10.1007\/s00393-020-00837-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"9 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"Y.H.\u00a0Lee and G.G.\u00a0Song have no financial or non-financial conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article, no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}